Have Insiders Been Buying Yield10 Bioscience, Inc. (NASDAQ:YTEN) Shares?

In this article:

We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examples of insiders dumping stock prior to a period of weak performance. So before you buy or sell Yield10 Bioscience, Inc. (NASDAQ:YTEN), you may well want to know whether insiders have been buying or selling.

What Is Insider Selling?

Most investors know that it is quite permissible for company leaders, such as directors of the board, to buy and sell stock in the company. However, most countries require that the company discloses such transactions to the market.

Insider transactions are not the most important thing when it comes to long-term investing. But equally, we would consider it foolish to ignore insider transactions altogether. As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

View our latest analysis for Yield10 Bioscience

Yield10 Bioscience Insider Transactions Over The Last Year

In the last twelve months, the biggest single purchase by an insider was when insider Jack Schuler bought US$668k worth of shares at a price of US$48.40 per share. That means that even when the share price was higher than US$0.18 (the recent price), an insider wanted to purchase shares. It's very possible they regret the purchase, but it's more likely they are bullish about the company. We always take careful note of the price insiders pay when purchasing shares. It is encouraging to see an insider paid above the current price for shares, as it suggests they saw value, even at higher levels. The only individual insider to buy over the last year was Jack Schuler.

You can see the insider transactions (by individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!

NasdaqCM:YTEN Recent Insider Trading, January 16th 2020
NasdaqCM:YTEN Recent Insider Trading, January 16th 2020

Yield10 Bioscience is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Insider Ownership of Yield10 Bioscience

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. We usually like to see fairly high levels of insider ownership. Our data indicates that Yield10 Bioscience insiders own about US$541k worth of shares (which is 9.8% of the company). Overall, this level of ownership isn't that impressive, but it's certainly better than nothing!

So What Do The Yield10 Bioscience Insider Transactions Indicate?

It doesn't really mean much that no insider has traded Yield10 Bioscience shares in the last quarter. However, our analysis of transactions over the last year is heartening. While we have no worries about the insider transactions, we'd be more comfortable if they owned more Yield10 Bioscience stock. Therefore, you should should definitely take a look at this FREE report showing analyst forecasts for Yield10 Bioscience.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Advertisement